Novo Nordisk A/S ADR (NVO): Price and Financial Metrics

Novo Nordisk A/S ADR (NVO): $159.81

-3.16 (-1.94%)

POWR Rating

Component Grades








Add NVO to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




#2 of 167

in industry

NVO Price/Volume Stats

Current price $159.81 52-week high $172.97
Prev. close $162.97 52-week low $95.02
Day low $159.43 Volume 1,257,200
Day high $161.83 Avg. volume 1,429,039
50-day MA $163.09 Dividend yield 1.04%
200-day MA $132.23 Market Cap 361.65B

NVO Stock Price Chart Interactive Chart >


  • Quality is the dimension where NVO ranks best; there it ranks ahead of 98.32% of US stocks.
  • NVO's strongest trending metric is Quality; it's been moving down over the last 179 days.
  • NVO ranks lowest in Value; there it ranks in the 74th percentile.

NVO Stock Summary

  • NVO has a higher market value than 99.65% of US stocks; more precisely, its current market capitalization is $368,858,400,000.
  • NOVO NORDISK A S's stock had its IPO on January 1, 1986, making it an older stock than 93.61% of US equities in our set.
  • NVO's price/sales ratio is 13.26; that's higher than the P/S ratio of 91.93% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NOVO NORDISK A S are JNJ, LLY, MA, WMT, and ABBV.
  • NVO's SEC filings can be seen here. And to visit NOVO NORDISK A S's official web site, go to

Novo Nordisk A/S ADR (NVO) Company Bio

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in BagsværdDenmark, with production facilities in nine countries, and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (45%) of its voting shares. (Source:Wikipedia)

NVO Latest News Stream

Event/Time News Detail
Loading, please wait...

NVO Latest Social Stream

Loading social stream, please wait...

View Full NVO Social Stream

Latest NVO News From Around the Web

Below are the latest news stories about NOVO NORDISK A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Pfizer stock rises on positive results from weight loss drug study

Yahoo Finance's Rachelle Akuffo details a rise in Pfizer stock after the company announced positive results from the study of a new weight loss drug.

Yahoo | May 22, 2023

Novo Nordisk's Oral Weight-Loss Drug Shows Significant Benefit

Novo Nordisk A/S (NYSE: NVO) announced headline results from OASIS 1 Phase 3a trial in the global OASIS program. OASIS 1 is a 68-week, efficacy, and safety trial comparing once-daily oral semaglutide 50 mg for weight management to a placebo in 667 adults with obesity or overweight with one or more comorbidities. Semaglutide is a peptide sold by Novo Nordisk under Ozempic, Rybelsus, and Wegovy for the long-term treatment of type 2 diabetes or obesity. The trial achieved its primary endpoint by de

Yahoo | May 22, 2023

Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss

An oral drug from Pfizer led to faster weight loss than weekly injections of Novo Nordisk's diabetes drug Ozempic. Pfizer stock jumped.

Yahoo | May 22, 2023

AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab

The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.

Yahoo | May 22, 2023

UPDATE 3-Pfizer's diabetes drug results in similar weight loss levels as Novo's Ozempic

Shares of Pfizer rose about 4.5% following the news, which comes at a time of increased investor interest in the weight-loss treatment market, which is estimated to reach $100 billion by the end of the decade. Pfizer's danuglipron, when given twice a day, lowered blood sugar in patients at all doses and reduced body weight at the highest dose after 16 weeks compared to placebo, according to mid-stage data published last year by the U.S. drugmaker.

Yahoo | May 22, 2023

Read More 'NVO' Stories Here

NVO Price Returns

1-mo -4.55%
3-mo 11.92%
6-mo 26.65%
1-year 46.13%
3-year 151.09%
5-year 258.08%
YTD 18.75%
2022 22.12%
2021 62.55%
2020 22.56%
2019 27.79%
2018 -12.54%

NVO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVO Dividend History

Continue Researching NVO

Want to see what other sources are saying about Novo Nordisk A S's financials and stock price? Try the links below:

Novo Nordisk A S (NVO) Stock Price | Nasdaq
Novo Nordisk A S (NVO) Stock Quote, History and News - Yahoo Finance
Novo Nordisk A S (NVO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!